European Journal of Health Economics

Papers
(The median citation count of European Journal of Health Economics is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Education and medication use later in life and the role of intelligence103
Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication54
Psychometric properties and general population reference values for PROMIS Global Health in Hungary38
The hidden cost of sophistication: economic complexity and obesity34
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries31
Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial30
Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis24
Domain-specific discounting of health and money: implications for health technology assessment23
Risk equalization and prevention23
Economic value of non-professional care in Spain. An analysis of the last decade22
Pragmatic randomized controlled trial comparing a complex telemedicine-based intervention with usual care in patients with chronic conditions22
Patient-level cost analysis of subfertility pathways in the Dutch healthcare system20
Comparing the measurement properties of the EQ-5D-Y-3L, EQ-5D-Y-5L and CHU9D in children and adolescents: a measurement property study20
Prescription opioids and economic hardship in France20
Cost awareness among intensivists in their daily clinical practice: a prospective multicentre study19
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan19
Nothing about us, without us? A reflection on and call for involving children in the process of valuing child health18
Replay to: Comparison of EQ-5D-5 L and EORTC QLU-C10D utilities in gastric cancer patients18
Setting incentives right with long-term risk adjustment18
Expensive today but cheaper tomorrow: lifetime costs of an active middle ear implant compared to alternative treatment options16
Primary care services and emergency department visits in blended fee-for-service and blended capitation models: evidence from Ontario, Canada16
From test to rest: evaluating socioeconomic differences along the COVID-19 care pathway in the Netherlands16
Workload and short sickness absences in a cohort of Finnish hospital employees16
Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system15
Real-world patterns of healthcare use, costs, and survival in diffuse large B-cell lymphoma: a nationwide Swedish register study15
Multinational stakeholder engagement to inform future development and refinement of the EuroQol toddler and infant populations (EQ-TIPS)15
Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma14
The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands14
Informing decisions in light of parameter uncertainty – an economic evaluation of the adjuvanted recombinant herpes zoster vaccine in Sweden14
Impact of postoperative in-hospital continuous vital sign monitoring on healthcare costs, resource utilization and labor market outcomes14
Health-related quality of life in patients with alcohol use disorder: comparing instruments and mapping from clinical measures to preference-based measures14
Mobile money and households’ ability to respond to health shocks in Africa: Evidence from Madagascar14
Comparing EQ-5D-5L and SF-6Dv2 utilities with QLU-C10D utilities in hematologic cancer patients13
Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade13
The causal effect of catastrophic health expenditure on poverty in Poland13
Breaking the rules: decision-making under absolute resource constraints13
On spillovers in economic evaluations: definition, mapping review and research agenda13
Life-cycle health effects of compulsory schooling12
Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany12
Benefits beyond health in the willingness to pay for a quality-adjusted life-year12
How perceptions of bone marrow donation costs affect donation behavior: survey evidence from a large donor registry12
Do EQ-5D-Y-3L value sets have common properties, and how do they compare to EQ-5D-5L value sets?12
Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands12
Correction: AOTMiT reimbursement recommendations compared to other HTA agencies12
The cost-effectiveness of value-based insurance design initiatives in managing cardiometabolic diseases: a systematic review12
A principled approach to non-discrimination in cost-effectiveness11
The trade-off between health system resiliency and efficiency: evidence from COVID-19 in European regions11
Healthcare costs of foodborne diseases in the United States: an analysis using electronic health records11
Psychometric properties comparison of EQ-5D-Y-3L and CHU-9D in children with adenoid hypertrophy11
Analyzing nurses’ decisions to leave their profession—a duration analysis11
The social value of gambling: surplus estimates by gambling types for France11
Availability of pharmacological treatments for multiple myeloma in Spain11
Do we agree on health state outcomes? A review of measurement agreement between time-trade off and other utility measures11
Economic value of diastasis repair with the use of mesh compared to no intervention in Italy10
The impacts of working from home on individual health and well-being10
Who pays and Who benefits? A distributional health-economic evaluation of strengthening the UK soft drinks industry levy10
Adverse selection and consumer inertia: empirical evidence from the Dutch health insurance market10
Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial model10
Time value of informal care of people with alzheimer’s disease in Spain: a population-based analysis10
Costs attributable to hypercholesterolemia in a single period and over the life cycle10
Estimating QALYs in adults with cerebral palsy: mapping the San Martin scale to the EQ-5D-5L for economic evaluation9
Is next generation sequencing for the diagnosis of rare diseases worth its cost? A user-based approach to valuation9
Changes in spending, quality indicators, and provider experiences following the introduction of a population-based payment model in dutch primary care: a mixed methods evaluation9
Valuation of the EQ-5D-3L in Jordan9
Does chronic disease coverage for outpatient care affect healthcare utilization and expenditures in China? Evidence from an administrative claim dataset9
Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis9
Do mobile hospital teams in residential aged care facilities increase health care efficiency: an evaluation of French residential care policy9
Evaluating hospital performance9
How tax structures for retail cannabis shape cannabis use among youth and young adults: evidence from a volumetric choice experiment9
Demographic and health impacts of women’s bodily autonomy: switching prescription requirements for emergency contraceptives9
Pharmacy cost groups for the German morbidity-based risk compensation scheme9
Cancer specific health utilities - QLU-C10D country value sets for Belgium, Hungary, Portugal and the Republic of Korea – an international valuation study8
Scales and size-quality outcomes in adult learning disability residential care: evidence from the UK8
Forward-looking Behavior in Health Insurance8
Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system8
The Italian National Health Service: still alive for long?8
Does medial tourism promote growth in healthcare sector?8
Tenders for generics and biosimilars: a challenging purchasing policy8
Cost-effectiveness analysis (CEA) of ovarian cancer preventive strategies for women with BRCA1/2 pathogenic variants: the role of surveillance8
Significant healthcare burden and life cost of spinal muscular atrophy: real-world data8
Measuring and decomposing income inequalities in child and adolescent mental health in the UK8
Alcohol prices, the April effect, and the environment, in violence-related injury in England and Wales8
Modeling European health systems: an ideal chain of services8
The ACA Medicaid expansions and abortion rates among young adults8
What hospital quality indicators matter to patients? Results from a general population survey8
Economic evaluation on dental caries preventive interventions for Australian children using a priority-setting approach7
Obtaining preference scores for an abbreviated self-completion version of the Teen-Addiction Severity Index (ASC T-ASI) to value therapy outcomes of systemic family interventions: a discrete choice ex7
Exploring the consequences of including off-patent prices in reimbursement decisions for patented drugs7
Cost-utility of cochlear implantation in single-sided deafness and asymmetric hearing loss: results of a randomized controlled trial7
How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals7
The link between physician motivation and care7
Getting fairer over time? Assessing changes in health technology funding processes using the accountability for reasonableness (A4R) framework7
Psychometric benefits of adding four bolt-ons (skin irritation, self-confidence, social relationships and sleep) to EQ-5D-5L compared to PROMIS-29 and Skindex-16 in patients with psoriasis and atopic 7
Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people7
Challenges for health systems seeking to embrace virtual health care for population health7
Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors6
Measuring outcomes for loneliness research: examining the appropriateness of the EQ-5D-5 L and EQ-HWB6
Referring physicians' intention to use hospital report cards for hospital referral purposes in the presence or absence of patient-reported outcomes: a randomized trial6
Assessing Taiwan’s pay-for-performance program for diabetes care: a cost–benefit net value approach6
Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD)6
Costs of productivity loss up to two years after ischaemic stroke6
Personnel shortages and the provision of long-term care: an empirical analysis of German nursing homes6
Paid and unpaid productivity losses across 28 European countries due to excess deaths and COVID-19 deaths from 2020 to 20236
Disclosing the ‘Big C’: what does cancer survivorship signal to employers?6
Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality6
Public preferences for saving lives versus life-years: evidence from a person-trade-off experiment in 12 countries during the COVID-19 pandemic6
Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy6
The health and long-term care costs in the last year of life in The Netherlands6
Self-interest, positional concerns and distributional considerations in healthcare preferences6
Does diagnostic testing always decrease antibiotics prescriptions?5
Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment5
Obesity and metabolic state are associated with increased healthcare resource and medication use and costs: a Finnish population-based study5
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy5
Time preferences and COVID-19 vaccination uptake5
The performance of the EQ-HWB-S as a measure of quality-of-life of caregivers in families that have experienced adverse events5
Ex ante evaluation of risk adjustment models for prospective provider payment: a conceptual framework and empirical application5
Health inequalities and subjective wellbeing5
Modeling European health systems: a theoretical exercise5
A critical review of the use of R2 in risk equalization research5
Generating EQ-5D-3L health utility scores from the Edinburgh Postnatal Depression Scale: a perinatal mapping study5
Closing the first wave of drug innovativeness in italy: final evidence from 2017 to 20255
Estimating cost savings from reducing antibiotic overprescription in european general practices5
One week versus three to five weeks of plaster cast immobilization for nonreduced distal radius fractures, a cost effectiveness analysis embedded in a stepped wedge cluster randomized controlled trial5
Does health technology assessment compromise access to pharmaceuticals?5
Health state utilities associated with X-linked retinitis pigmentosa (XLRP)5
Unravelling heterogeneity in efficiency measurements: a case study of public hospitals in Spain5
Comparing EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases5
A systematic review of economic models comparing in-centre haemodialysis interventions: challenges for demonstrating cost-effectiveness in the context of high background dialysis costs5
The effect of displaying laboratory test prices on physicians’ ordering behaviour: a systematic review of European studies5
A cross-country comparison of the psychometric performance of SF-6Dv2 and EQ-5D-5L5
Long-term costs associated with healthcare use of people with cancer in Scotland5
The inpatient economic burden of antibiotic resistance in Switzerland: a regression-based analysis4
The societal cost of ‘unwanted’ loneliness in Spain4
Translating the EORTC CAT core and the QLQ-C30 to the EQ-5D-5L in patients with metastatic breast cancer: A comparison of direct and indirect mapping algorithms4
Productivity costs associated with premature deaths due to acute myocardial infarction in Spain: analysis from 2013 to 20224
Does opt-out legislation crowd out living organ donations? A cross-country study4
Out-of-pocket costs sustained in the last 12 months by cancer patients: an Italian survey-based study on individual expenses between 2017 and 20184
Mapping of the EORTC QLQ-LC43 to EQ-5D-5 L index in patients with lung cancer: comparison of traditional regression models with machine learning technique4
Different family caregiver- and care recipient-related factors are associated with the cost of care in the early, mild, and moderate stages of Alzheimer’s disease in Finland: A 5-year ALSOVA study4
Risk, time preferences, trustworthiness and COVID-19 preventive behavior: evidence from France4
Valuation of EQ-5D-5L health states from cancer patients’ perspective: a feasibility study4
Willingness to pay for a quality adjusted life year across different time horizons: direct elicitation in Quebec4
Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study4
Cost-effectiveness analysis of the covered endovascular reconstruction of the aortic bifurcation versus kissing stents and open surgical repair for the treatment of aorto-iliac occlusive disease4
Health sector corruption and access to healthcare in Africa4
Critical issues with methods and results interpretation at validating the EQ-5D-5L and QLU-C10D utilities in gastric cancer patients4
Making the rules make sense: valuation of constrained resources4
Assessing the relation between financial performance and long-term bank loan interest rates for healthcare providers in the Netherlands: a panel data analysis4
EQ-5D-5L Portuguese population norms4
Assessing the economic burden of complicated urinary tract infection: A systematic literature review4
Correction: Lifetime direct healthcare costs of treating colorectal cancer: a systematic review4
New evidence on supplier-induced demand in China’s public tertiary hospitals: is the cost of hospitalization higher in the off-season?4
Breaking the habit: a systematic review of the cost-effectiveness of non-pharmacological and combined interventions for smoking cessation in Europe4
Total costs of different lines of treatment in diffuse large B-cell lymphoma in Denmark – a real-world data analysis4
Validity and responsiveness of EQ-5D-Y in children with haematological malignancies and their caregivers4
Were we happy and we didn’t know it? A subjective dynamic and financial assessment pre-, during and post-COVID-194
Does a free maternity policy in Kenya work? Impact and cost–benefit consideration based on demographic health survey data4
Cost-effectiveness and cost-utility analysis of a nurse-led, transitional care model to improve care coordination for patients with cardiovascular diseases: results from the “Cardiolotse” study4
A cost-of-illness study of Behçet syndrome in Italy4
Economic burden of eosinophilic esophagitis in the first year after diagnosis in Spain: A direct medical cost analysis4
Non-communicable diseases, COVID-19 and labour market outcomes4
Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries3
The value of social robots supporting informal care: a discrete choice experiment among informal caregivers3
Cost-effectiveness analysis of influenza vaccination with high-dose vaccine versus standard-dose quadrivalent vaccine in older adults in Spain3
The economic burden of asthma in Italy: evaluating the potential impact of different treatments in adult patients with severe eosinophilic asthma3
Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries3
Population normative data for OxCAP-MH capability scores3
The handling of missing data in trial-based economic evaluations: should data be multiply imputed prior to longitudinal linear mixed-model analyses?3
A state-level analysis of macro-level factors associated with hospital readmissions3
Migration-related determinants of health-care service utilization among persons with a direct migration background in Germany: an exploratory study based on the German Socio-Economic Panel (SOEP)3
Promoting healthy behaviour with financial incentives: three challenges and solutions for large scale implementation3
Estimating the health-related quality of life burden attributable to illicit drug use in Australian adults3
Informal care at old age at home and in nursing homes: determinants and economic value3
The Impact of Health Technology Assessment on Pharmaceutical Prices: Evidence from Germany3
Broadening sources of finance for health promotion and disease prevention: Smart capacitating investment3
Pricing of innovative medicines and advanced therapies worldwide: an scoping review3
The impact of parastomal hernia on quality of life using data from the CIPHER prospective cohort study3
Message from the New Editor-in-Chief3
Cancer-specific utility: clinical validation of the EORTC QLU-C10D in patients with glioblastoma3
Early start of anti-dementia medication is associated with lower health and social care costs in Alzheimer´s patients: a Finnish nationwide register study3
Public versus private healthcare systems in the OECD area– a broad evaluation of performance3
Safety and economic benefits of early hospital-at-home transfer after kidney transplantation: a propensity-score matched study from Spain3
Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose3
A systematic review of the cost-effectiveness of interventions to increase cervical cancer screening among underserved women in Europe3
Comparison of four approaches in eliciting health state utilities with SF-6Dv23
The effect of age-specific stay-at-home recommendation on healthcare utilization: Evidence from Finland’s COVID-19 policy3
Budget impact analysis of Oncotype DX® multigenic prognostic test in patients with early breast cancer in Italy3
Variation in patient-reported outcomes after total hip replacement across ten high-volume hospitals in Germany: results from a multicenter, prospective, longitudinal Cohort Study3
Comparison of the EQ-5D-Y and the CHU-9D instruments in a general child population based on self-reports and proxy-reports3
Business cycles and mortality in Italy3
Impact of Long COVID on productivity and informal caregiving3
Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis3
Routine measurement in low back pain; towards a pragmatic patient-reported productivity cost outcome measurement using the institute for medical technology assessment productivity cost questionnaire3
Loss aversion in EQ-5D-Y-3L: does it explain differences in willingness to trade-off life years in adults and children?3
Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients3
Willingness to pay for measures to increase use of active school transport3
The effect of telephone health coaching and remote exercise monitoring for peripheral artery disease (TeGeCoach) on health care cost and utilization: results of a randomized controlled trial3
Do institutions matter for citizens’ health status? Empirical evidence from Italy2
Is there a link between health care utilisation and subjective well-being? An exploratory study among older Danes2
Far more than a shot in the arm: Vaccines and consumer spending2
Estimating the willingness-to-pay to avoid the consequences of foodborne illnesses: a discrete choice experiment2
Healthcare information management and operational cost performance: empirical evidence2
Test-retest reliability of the Online Elicitation of Personal Utility Functions (OPUF) approach for valuing the EQ-HWB-S2
Points to consider for incorporating climate impacts into health economic evaluation2
Are there differences in health state preferences between urban and rural respondents? a comparison using time trade-off and discrete choice experiment2
Does uptake of specialty care affect HRQoL development in COPD patients beneficially? A difference-in-difference analysis linking claims and survey data2
Nexus among health expenditures, ICTs and sustainable economic growth: Insights from South Asian Nationals health and economic issues2
Exploring the social value and design preferences for a home-based dementia community program in Australia2
What remains after the money ends? Evidence on whether admission reductions continued following the largest health and social care integration programme in England2
How do family doctors respond to reduced waiting times for cancer diagnosis in secondary care?2
Exploring non-iterative time trade-off methods for valuation of EQ-5D-5L health states2
Health shocks and health behavior: a long-term perspective2
Dividend policy issues in the European pharmaceutical industry: new empirical evidence2
Country-level effects of diagnosis-related groups: evidence from Germany’s comprehensive reform of hospital payments2
TF-TAVI and SAVR post-procedural complications in Germany 2021/2022 – impact on healthcare resource consumption2
Pembrolizumab vs. chemotherapy in the first-line setting of PD-L1 ≥ 50% metastatic non-small cell lung cancer: a real-world cost-effectiveness analysis2
Age, morbidity, and time to death: End-of-life expenditures on health care for the young-old population2
Health-related quality of life assessed by EQ-5D-5L and its determinants among rural adults: result from the Henan rural cohort study2
Bridging success in the labour market: does continuity of general practitioners’ care matter for individuals with common mental disorders?2
Measuring EQ-5D-5L utility values in parents who have experienced perinatal death2
Short- and intermediate-term impact of DTC telemedicine consultations on subsequent healthcare consumption2
Completing the time trade-off with respondents who are older, in poorer health or with an immigrant background in an EQ-5D-5L valuation study2
Repurposing biosimilars, rethinking costs: a framework for sustainable drug pricing for repurposed bevacizumab for intravitreal injections2
Nonprofit behavior altered by monetary donations: evidence from the U.S. hospice industry2
Cost-effectiveness of Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy using a French healthcare perspective2
The EORTC QLU-C10D: the Hong Kong valuation study2
The EQ-5D-3L valuation study for Bermuda: using an on-line EQ-VT protocol2
Willingness to pay for health gains from an international integrated early warning system for infectious disease outbreaks2
Cost-effectiveness analysis of procalcitonin and lung ultrasonography guided antibiotic prescriptions in primary care2
The add-on list cannot do it all: a comparative economic evaluation of equity impacts in the German and French inpatient care sectors2
Validation of EQ-HWB-9 among Chinese college students based on a nationwide survey2
Cash-for-care and its impact on older adults’ informal and formal long-term care use: evidence from continental European countries2
Economic and human burden attributable to antimicrobial resistance in Spain: a holistic macro-estimation of costs2
Cost-effectiveness of TAVI in the United Kingdom: a long-term analysis based on 4-year data from the Evolut Low Risk Trial2
Population norms for the EQ-5D-5L for Hungary: comparison of online surveys and computer assisted personal interviews2
The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study2
Is EQ-5D-5L better than EQ-5D-3L? A comparison of descriptive systems and utility scores in patients with kidney chronic disease2
Length of hospital stays and financial incentives: evidence from Dutch rehabilitation centers2
Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries2
Comparing the measurement properties of the EQ-5D-5 L, SF-6Dv2, QLU-C10D and FACT-8D among survivors of classical Hodgkin’s lymphoma2
Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma2
Changes in disposable income of Polish households and growing trends in alcohol mortality2
United Kingdom value set for the functional assessment of cancer therapy eight dimension (FACT-8D) preference-based quality of life instrument2
Bayesian cost-effectiveness analysis of Whole genome sequencing versus Whole exome sequencing in a pediatric population with suspected genetic disorders2
“COVID-19 and income inequality in OECD countries:” A methodological comment2
Costs associated with insufficient physical activity in Germany: cross-sectional results from the baseline examination of the German national cohort (NAKO)2
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France2
To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study2
0.12610483169556